Literature DB >> 17235521

Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.

Roland Sänger1, Ulrich Behre, Karl-Heinz Krause, Hans-Peter Loch, Peter Soemantri, Dietmar Herrmann, Eugenie Schmitz-Hauss, Joanne Wolter, Bernard Hoet.   

Abstract

Reduced-antigen-content pertussis vaccines designed initially for booster vaccination of adolescents and adults can also be used to vaccinate pre-school age children. Combination vaccines, which reduce the number of administered injections, combine multiple antigens including inactivated poliovirus (IPV), which is recommended in this age group in some countries. This randomised, controlled study compared a combined diphtheria-tetanus-acellular pertussis-inactivated polio-containing booster vaccine, dTpa-IPV (Boostrix Polio, n=822), to separately administered dTpa (Boostrix) and IPV (IPV Mérieux, n=136) in 4-8-year-old children who had previously received four doses of DTPa. Additional serological assessment was performed 1 year after the booster dose. One month after vaccination, seroprotection/vaccine response rates were similar for both groups. At least 99.9% of the subjects had protective antibodies against diphtheria, tetanus and polio, and at least 90.1% had a vaccine response to pertussis antigens after dTpa-IPV. Reactogenicity of dTpa-IPV was comparable to dTpa + IPV. Fever and grade 3 loss of appetite occurred more commonly after dTpa-IPV, whereas swelling and grade 3 pain occurred more frequently after separately administered dTpa + IPV (P<0.05 for all). However, 95% CIs overlapped in all cases. Large swelling reactions after dTpa-IPV occurred less commonly than have been reported after a fifth dose of DTPa. One year after the booster, 98.6% of the subjects tested continued to have protective antibodies against diphtheria, tetanus and polio, and at least 81.2% were seropositive for pertussis components. The reduced-antigen-content dTpa-IPV vaccine was immunogenic, well tolerated and safe in pre-school age children. It provides immunity against four diseases in a single injection, with the potential reactogenicity benefit of a reduced-antigen dose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235521     DOI: 10.1007/s00431-006-0403-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

Review 1.  The science and fiction of pertussis vaccines.

Authors:  J D Cherry; P Olin
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

2.  Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens.

Authors:  D W Scheifele; S A Halperin; A C Ferguson
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

3.  Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children.

Authors:  C L Collins; P Salt; N McCarthy; T Chantler; L Lane; F Hemme; L Diggle; J Buttery; N R E Kitchin; E R Moxon; A J Pollard
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

4.  Effect of the preschool pertussis booster on national notifications of disease in Australia.

Authors:  Siranda Torvaldsen; Peter B McIntyre
Journal:  Pediatr Infect Dis J       Date:  2003-11       Impact factor: 2.129

5.  A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Authors:  M E Pichichero; M A Deloria; M B Rennels; E L Anderson; K M Edwards; M D Decker; J A Englund; M C Steinhoff; A Deforest; B D Meade
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

6.  Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

Authors:  A E Tozzi; A Anemona; P Stefanelli; S Salmaso; M L Ciofi degli Atti; P Mastrantonio; A Giammanco
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

7.  How common is whooping cough in a nonvaccinating country?

Authors:  J Isacson; B Trollfors; J Taranger; G Zackrisson; T Lagergård
Journal:  Pediatr Infect Dis J       Date:  1993-04       Impact factor: 2.129

8.  Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age.

Authors:  Rodrigo Vergara; Miguel Tregnaghi; José Ussher; Sofía Navarro; Ricardo Rüttimann; Marcela Potin; Joanne Wolter; Lode Schuerman
Journal:  Eur J Pediatr       Date:  2005-03-22       Impact factor: 3.183

9.  Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model.

Authors:  Brigitte Cheuvart; Margaret Burgess; Fred Zepp; Jussi Mertsola; Joanne Wolter; Lode Schuerman
Journal:  Vaccine       Date:  2004-12-02       Impact factor: 3.641

10.  Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact.

Authors:  Danuta M Skowronski; Valencia P Remple; Jane Macnabb; Karen Pielak; David M Patrick; Scott A Halperin; David Scheifele
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

View more
  10 in total

1.  Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.

Authors:  Rose-Minke Schure; Lotte H Hendrikx; Lia G H de Rond; Kemal Oztürk; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2013-07-03

2.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

3.  The number of injected same-day preschool vaccines relates to preadolescent needle fear and HPV uptake.

Authors:  Amy L Baxter; Lindsey L Cohen; Mark Burton; Anaam Mohammed; M Louise Lawson
Journal:  Vaccine       Date:  2017-06-21       Impact factor: 3.641

4.  Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.

Authors:  Giuseppe Ferrera; Mario Cuccia; Gabriele Mereu; Giancarlo Icardi; Gianni Bona; Susanna Esposito; Federico Marchetti; Marc Messier; Sherine Kuriyakose; Karin Hardt
Journal:  Hum Vaccin Immunother       Date:  2012-02-13       Impact factor: 3.452

5.  Combination vaccines.

Authors:  David Ag Skibinski; Barbara C Baudner; Manmohan Singh; Derek T O'Hagan
Journal:  J Glob Infect Dis       Date:  2011-01

6.  Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children.

Authors:  Jeanet M Kemmeren; Nicoline A T van der Maas; Hester E de Melker
Journal:  Eur J Pediatr       Date:  2010-09-21       Impact factor: 3.860

7.  Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents--A single blind randomized trial.

Authors:  Noris Pavia-Ruz; Katia Abarca; Alejandro Lepetic; Maria Yolanda Cervantes-Apolinar; Karin Hardt; Girish Jayadeva; Sherine Kuriyakose; Htay Htay Han; Manuel de la O
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Booster vaccination: the role of reduced antigen content vaccines as a preschool booster.

Authors:  Giovanni Gabutti; Cecilia Trucchi; Michele Conversano; Giambattista Zivelonghi; Giorgio Zoppi
Journal:  Biomed Res Int       Date:  2014-02-11       Impact factor: 3.411

9.  Use of tetanus-diphtheria (Td) vaccine in children 4-7 years of age: World Health Organization consultation of experts.

Authors:  Shalini Desai; Heather M Scobie; Thomas Cherian; Tracey Goodman
Journal:  Vaccine       Date:  2020-01-23       Impact factor: 3.641

10.  Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age.

Authors:  Rose-Minke Schure; Lia de Rond; Kemal Oztürk; Lotte Hendrikx; Elisabeth Sanders; Guy Berbers; Anne-Marie Buisman
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.